tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Gao G et al. Rapamycin inhibits hydrogen peroxide-induced loss of vascular contractility. 2011 Am. J. Physiol. Heart Circ. Physiol. pmid:21357511
DuBell WH et al. K(+) currents responsible for repolarization in mouse ventricle and their modulation by FK-506 and rapamycin. 2000 Am. J. Physiol. Heart Circ. Physiol. pmid:10710358
Giordano A et al. Differential effect of atorvastatin and tacrolimus on proliferation of vascular smooth muscle and endothelial cells. 2012 Am. J. Physiol. Heart Circ. Physiol. pmid:22058159
Hafizi S et al. ANG II activates effectors of mTOR via PI3-K signaling in human coronary smooth muscle cells. 2004 Am. J. Physiol. Heart Circ. Physiol. pmid:15317677
Liu Y et al. Transcription factor CHF1/Hey2 regulates EC coupling and heart failure in mice through regulation of FKBP12.6. 2012 Am. J. Physiol. Heart Circ. Physiol. pmid:22408025
Sasamori K et al. Cyclic ADP-ribose, a putative Ca2+-mobilizing second messenger, operates in submucosal gland acinar cells. 2004 Am. J. Physiol. Lung Cell Mol. Physiol. pmid:14990397
Lum H et al. Protein phosphatase 2B inhibitor potentiates endothelial PKC activity and barrier dysfunction. 2001 Am. J. Physiol. Lung Cell Mol. Physiol. pmid:11504680
Yaghi A and Sims SM Constrictor-induced translocation of NFAT3 in human and rat pulmonary artery smooth muscle. 2005 Am. J. Physiol. Lung Cell Mol. Physiol. pmid:16055480
Bouvier N et al. Cyclosporine triggers endoplasmic reticulum stress in endothelial cells: a role for endothelial phenotypic changes and death. 2009 Am. J. Physiol. Renal Physiol. pmid:18987109
Ren H et al. Phosphatase inhibition increases AQP2 accumulation in the rat IMCD apical plasma membrane. 2016 Am. J. Physiol. Renal Physiol. pmid:27488997
Thai TL et al. ADP-ribosyl cyclase and ryanodine receptor activity contribute to basal renal vasomotor tone and agonist-induced renal vasoconstriction in vivo. 2007 Am. J. Physiol. Renal Physiol. pmid:17652368
Peherstorfer E et al. Effects of microinjection of synthetic Bcl-2 domain peptides on apoptosis of renal tubular epithelial cells. 2002 Am. J. Physiol. Renal Physiol. pmid:12060601
Axelsson J et al. Scavengers of reactive oxygen species, paracalcitol, RhoA, and Rac-1 inhibitors and tacrolimus inhibit angiotensin II-induced actions on glomerular permeability. 2013 Am. J. Physiol. Renal Physiol. pmid:23657856
Mohebbi N et al. The calcineurin inhibitor FK506 (tacrolimus) is associated with transient metabolic acidosis and altered expression of renal acid-base transport proteins. 2009 Am. J. Physiol. Renal Physiol. pmid:19439519
Cho SG et al. Drp1 dephosphorylation in ATP depletion-induced mitochondrial injury and tubular cell apoptosis. 2010 Am. J. Physiol. Renal Physiol. pmid:20410216
De Miguel C et al. Infiltrating T lymphocytes in the kidney increase oxidative stress and participate in the development of hypertension and renal disease. 2011 Am. J. Physiol. Renal Physiol. pmid:21159736
Rojas-Vega L et al. Increased phosphorylation of the renal Na+-Cl- cotransporter in male kidney transplant recipient patients with hypertension: a prospective cohort. 2015 Am. J. Physiol. Renal Physiol. pmid:26336164
Edinger RS et al. Effect of immunosuppressive agents on glucocorticoid receptor function in A6 cells. 2002 Am. J. Physiol. Renal Physiol. pmid:12110508
Ilori TO et al. Acute calcineurin inhibition with tacrolimus increases phosphorylated UT-A1. 2012 Am. J. Physiol. Renal Physiol. pmid:22205230
Amberg GC et al. Regulation of A-type potassium channels in murine colonic myocytes by phosphatase activity. 2001 Am. J. Physiol., Cell Physiol. pmid:11698261
Ahn HS et al. Calcineurin-independent inhibition of KV1.3 by FK-506 (tacrolimus): a novel pharmacological property. 2007 Am. J. Physiol., Cell Physiol. pmid:17166943
Wang YX et al. FKBP12.6 and cADPR regulation of Ca2+ release in smooth muscle cells. 2004 Am. J. Physiol., Cell Physiol. pmid:14592808
Sans MD and Williams JA Calcineurin is required for translational control of protein synthesis in rat pancreatic acini. 2004 Am. J. Physiol., Cell Physiol. pmid:15044154
Bayguinov O et al. Muscarinic stimulation increases basal Ca(2+) and inhibits spontaneous Ca(2+) transients in murine colonic myocytes. 2001 Am. J. Physiol., Cell Physiol. pmid:11171588
Angus LM et al. Calcineurin-NFAT signaling, together with GABP and peroxisome PGC-1{alpha}, drives utrophin gene expression at the neuromuscular junction. 2005 Am. J. Physiol., Cell Physiol. pmid:15930144
Zhang Y et al. K restriction inhibits protein phosphatase 2B (PP2B) and suppression of PP2B decreases ROMK channel activity in the CCD. 2008 Am. J. Physiol., Cell Physiol. pmid:18184875
Yue G et al. The effect of rapamycin on single ENaC channel activity and phosphorylation in A6 cells. 2000 Am. J. Physiol., Cell Physiol. pmid:10898719
Nam JH et al. Expression of TASK-2 and its upregulation by B cell receptor stimulation in WEHI-231 mouse immature B cells. 2011 Am. J. Physiol., Cell Physiol. pmid:21307343
Nakagawa K et al. Immunosuppression with tacrolimus improved reproductive outcome of women with repeated implantation failure and elevated peripheral blood TH1/TH2 cell ratios. 2015 Am. J. Reprod. Immunol. pmid:25394810
Nakagawa K et al. Immunosuppressive treatment using tacrolimus promotes pregnancy outcome in infertile women with repeated implantation failures. 2017 Am. J. Reprod. Immunol. pmid:28466977
Saito S et al. Role of Paternal Antigen-Specific Treg Cells in Successful Implantation. 2016 Am. J. Reprod. Immunol. pmid:26706630
Kofod L et al. Endometrial immune markers are potential predictors of normal fertility and pregnancy after in vitro fertilization. 2017 Am. J. Reprod. Immunol. pmid:28440588
Tabata C et al. Calcineurin/NFAT pathway: a novel regulator of parturition. 2009 Am. J. Reprod. Immunol. pmid:19527231
Goldthorpe H et al. Occlusive lung arterial lesions in endothelial-targeted, fas-induced apoptosis transgenic mice. 2015 Am. J. Respir. Cell Mol. Biol. pmid:25879383
Fujiki M et al. Role of T cells in bronchoalveolar space in the development of interstitial pneumonia induced by superantigen in autoimmune-prone mice. 1999 Am. J. Respir. Cell Mol. Biol. pmid:10572064
Deuse T et al. Mechanisms behind local immunosuppression using inhaled tacrolimus in preclinical models of lung transplantation. 2010 Am. J. Respir. Cell Mol. Biol. pmid:19880819
Rolfe FG et al. Cyclosporin A and FK506 reduce interleukin-5 mRNA abundance by inhibiting gene transcription. 1997 Am. J. Respir. Cell Mol. Biol. pmid:9271313
Yerkovich ST et al. Survival after bronchiolitis obliterans syndrome. 2011 Am. J. Respir. Crit. Care Med. pmid:21325085
Bhorade S et al. Comparison of sirolimus with azathioprine in a tacrolimus-based immunosuppressive regimen in lung transplantation. 2011 Am. J. Respir. Crit. Care Med. pmid:20833822
Koshika T et al. Pretreatment with FK506 improves survival rate and gas exchange in canine model of acute lung injury. 2001 Am. J. Respir. Crit. Care Med. pmid:11208629
Saeki K et al. Endobronchial Lesions of Mycobacterium abscessus Infection in an Immunocompromised Patient. 2017 Am. J. Respir. Crit. Care Med. pmid:28199133
Joshi MS et al. Calcineurin regulates myocardial function during acute endotoxemia. 2006 Am. J. Respir. Crit. Care Med. pmid:16424445
Fauvel H et al. Protective effects of cyclosporin A from endotoxin-induced myocardial dysfunction and apoptosis in rats. 2002 Am. J. Respir. Crit. Care Med. pmid:11850335
Spiekerkoetter E et al. Low-Dose FK506 (Tacrolimus) in End-Stage Pulmonary Arterial Hypertension. 2015 Am. J. Respir. Crit. Care Med. pmid:26177174
Raofi V et al. A prospective randomized trial comparing the efficacy of tacrolimus versus cyclosporine in black recipients of primary cadaveric renal transplants. 1999 Am. J. Surg. pmid:10326847
Tanaka K et al. Living related liver transplantation in children. 1994 Am. J. Surg. pmid:7517649
Li X et al. Increased iNOS-expressing macrophage in long-term surviving rat small-bowel grafts. 2007 Am. J. Surg. pmid:17618815
Rabkin JM et al. Immunosuppression impact on long-term cardiovascular complications after liver transplantation. 2002 Am. J. Surg. pmid:12034401
Jurim O et al. Living-donor liver transplantation at UCLA. 1995 Am. J. Surg. pmid:7538267
Lee KK et al. Successful treatment of ongoing intestinal allograft rejection permits recovery of graft structure and function. 1993 Am. J. Surg. pmid:7678188
Finn L et al. Epstein-Barr virus infections in children after transplantation of the small intestine. 1998 Am. J. Surg. Pathol. pmid:9500771
Randhawa PS et al. The histopathological changes associated with allograft rejection and drug toxicity in renal transplant recipients maintained on FK506. Clinical significance and comparison with cyclosporine. 1993 Am. J. Surg. Pathol. pmid:7680544
Minervini MI et al. Acute renal allograft rejection with severe tubulitis (Banff 1997 grade IB). 2000 Am. J. Surg. Pathol. pmid:10757402
Randhawa PS et al. Microvascular changes in renal allografts associated with FK506 (Tacrolimus) therapy. 1996 Am. J. Surg. Pathol. pmid:8772784
Schnitzler M Diabetes mellitus after kidney transplantation in the United States. 2003 Am. J. Transplant. pmid:14510709
Spada M et al. Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression. 2006 Am. J. Transplant. pmid:16771811
Frassetto LA et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. 2007 Am. J. Transplant. pmid:17949460
Saliba F et al. Efficacy and Safety of Everolimus and Mycophenolic Acid With Early Tacrolimus Withdrawal After Liver Transplantation: A Multicenter Randomized Trial. 2017 Am. J. Transplant. pmid:28133906
Levitsky J and Feng S Sirolimus and mTOR inhibitors in liver transplantation: the wheel has come full circle. 2014 Am. J. Transplant. pmid:24620373
de Fijter JW et al. Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial. 2017 Am. J. Transplant. pmid:28027625
Trofe-Clark J et al. Immunosuppression, generic drugs and the FDA. 2012 Am. J. Transplant. pmid:22176626
English RF et al. Long-term comparison of tacrolimus- and cyclosporine-induced nephrotoxicity in pediatric heart-transplant recipients. 2002 Am. J. Transplant. pmid:12243498
Asrani SK et al. De novo sirolimus and reduced-dose tacrolimus versus standard-dose tacrolimus after liver transplantation: the 2000-2003 phase II prospective randomized trial. 2014 Am. J. Transplant. pmid:24456026
Song L et al. ASP2409, A Next-Generation CTLA4-Ig, Versus Belatacept in Renal Allograft Survival in Cynomolgus Monkeys. 2017 Am. J. Transplant. pmid:27598231
Ekberg H et al. Calcineurin inhibitor minimization in the Symphony study: observational results 3 years after transplantation. 2009 Am. J. Transplant. pmid:19563339
Duncan FJ et al. Clinically relevant immunosuppressants influence UVB-induced tumor size through effects on inflammation and angiogenesis. 2007 Am. J. Transplant. pmid:17941958
Hu X et al. Chimeric Allografts Induced by Short-Term Treatment With Stem Cell-Mobilizing Agents Result in Long-Term Kidney Transplant Survival Without Immunosuppression: A Study in Rats. 2016 Am. J. Transplant. pmid:26749344
Cameron AM et al. Chimeric Allografts Induced by Short-Term Treatment With Stem Cell Mobilizing Agents Result in Long-Term Kidney Transplant Survival Without Immunosuppression: II, Study in Miniature Swine. 2016 Am. J. Transplant. pmid:26748958
Flechner SM et al. Allotransplantation of cryopreserved parathyroid tissue for severe hypocalcemia in a renal transplant recipient. 2010 Am. J. Transplant. pmid:20883540
Benítez CE et al. ATG-Fresenius treatment and low-dose tacrolimus: results of a randomized controlled trial in liver transplantation. 2010 Am. J. Transplant. pmid:20883560
Madariaga ML et al. Kidney-induced cardiac allograft tolerance in miniature swine is dependent on MHC-matching of donor cardiac and renal parenchyma. 2015 Am. J. Transplant. pmid:25824550
Pescovitz MD et al. A randomized, double-blind, pharmacokinetic study of oral maribavir with tacrolimus in stable renal transplant recipients. 2009 Am. J. Transplant. pmid:19663892
Vanrenterghem Y et al. Minimization of immunosuppressive therapy after renal transplantation: results of a randomized controlled trial. 2005 Am. J. Transplant. pmid:15636615
Bryan CF et al. Long-term survival of kidneys transplanted from live A2 donors to O and B recipients. 2007 Am. J. Transplant. pmid:17359511
Vincenti F et al. Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. 2007 Am. J. Transplant. pmid:17359512
Cendales L et al. Tacrolimus to Belatacept Conversion Following Hand Transplantation: A Case Report. 2015 Am. J. Transplant. pmid:25773260
Jaksch P et al. Alemtuzumab in lung transplantation: an open-label, randomized, prospective single center study. 2014 Am. J. Transplant. pmid:25039364
Neuberger JM et al. Delayed introduction of reduced-dose tacrolimus, and renal function in liver transplantation: the 'ReSpECT' study. 2009 Am. J. Transplant. pmid:19120077
Tan HP et al. Two hundred living donor kidney transplantations under alemtuzumab induction and tacrolimus monotherapy: 3-year follow-up. 2009 Am. J. Transplant. pmid:19120078
Ashman N et al. Belatacept as maintenance immunosuppression for postrenal transplant de novo drug-induced thrombotic microangiopathy. 2009 Am. J. Transplant. pmid:19120084
Asrani SK and O'Leary JG Can one pill a day keep rejection away? 2015 Am. J. Transplant. pmid:25703394
Bhorade SM et al. Comparison of three tacrolimus-based immunosuppressive regimens in lung transplantation. 2003 Am. J. Transplant. pmid:14629288
Vongwiwatana A et al. Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy. 2004 Am. J. Transplant. pmid:14678043
Awadalla Y et al. HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. 2004 Am. J. Transplant. pmid:15367226
Okabayashi T et al. Mobilization of host stem cells enables long-term liver transplant acceptance in a strongly rejecting rat strain combination. 2011 Am. J. Transplant. pmid:21883903
Hellemons ME et al. Former smoking is a risk factor for chronic kidney disease after lung transplantation. 2011 Am. J. Transplant. pmid:21883906
Schrepfer S et al. Effect of inhaled tacrolimus on cellular and humoral rejection to prevent posttransplant obliterative airway disease. 2007 Am. J. Transplant. pmid:17532751
Montgomery SP et al. Efficacy and toxicity of a protocol using sirolimus, tacrolimus and daclizumab in a nonhuman primate renal allotransplant model. 2002 Am. J. Transplant. pmid:12118862
Ahsan N et al. Limited dose monoclonal IL-2R antibody induction protocol after primary kidney transplantation. 2002 Am. J. Transplant. pmid:12118902
Pallet N et al. Kidney transplant recipients carrying the CYP3A4*22 allelic variant have reduced tacrolimus clearance and often reach supratherapeutic tacrolimus concentrations. 2015 Am. J. Transplant. pmid:25588704
Teuteberg JJ et al. Alemtuzumab induction prior to cardiac transplantation with lower intensity maintenance immunosuppression: one-year outcomes. 2010 Am. J. Transplant. pmid:19889126
Haufroid V et al. CYP3A5 and ABCB1 polymorphisms and tacrolimus pharmacokinetics in renal transplant candidates: guidelines from an experimental study. 2006 Am. J. Transplant. pmid:17049058
Gaston RS et al. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. 2009 Am. J. Transplant. pmid:19459794
Lake JR et al. Addition of MMF to dual immunosuppression does not increase the risk of malignant short-term death after liver transplantation. 2005 Am. J. Transplant. pmid:16303011
Turgut F and Akcay A Renal function estimation in cirrhosis. 2009 Am. J. Transplant. pmid:19519814
Irish WD et al. Cyclosporine versus tacrolimus treated liver transplant recipients with chronic hepatitis C: outcomes analysis of the UNOS/OPTN database. 2011 Am. J. Transplant. pmid:21564522
Friman S et al. Sotrastaurin, a novel small molecule inhibiting protein-kinase C: randomized phase II study in renal transplant recipients. 2011 Am. J. Transplant. pmid:21564523
Margreiter R et al. Alemtuzumab (Campath-1H) and tacrolimus monotherapy after renal transplantation: results of a prospective randomized trial. 2008 Am. J. Transplant. pmid:18510632
Mandelbrot DA et al. Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus. 2015 Am. J. Transplant. pmid:26176342
Rogers J et al. Effect of ethnicity on outcome of simultaneous pancreas and kidney transplantation. 2003 Am. J. Transplant. pmid:14510702